CareFusion’s spin-off from Cardinal Health set for mid-year
This article was originally published in The Gray Sheet
Executive Summary
Cardinal Health will spin off its clinical and medical products businesses - representing $4 billion in annual sales - by mid-year, according to the company. Given the name "CareFusion" on Feb. 16, the spin-off entity will include Alaris infusion pumps, Avea respirators, Pyxis medication dispensing systems, the MedMined electronic infection surveillance service, and ChloraPrep skin preparation products. The new firm will be based in San Diego, have 13,000 employes, and is expected to trade on the New York Stock Exchange under the symbol "CFN." The spin-off has been in the works since last summer (1"The Gray Sheet" Aug. 11, 2008, In Brief)
You may also be interested in...
Cardinal spin-off?
Cardinal Health is weighing the possibility of spinning off its $5.6 billion clinical and medical products business as a separate, publicly traded company, the firm said Aug. 7. Last month, Cardinal consolidated its two major business activities of health care product sales and its $80 billion distributor operation into two distinct business units and cut 600 jobs (1"The Gray Sheet" July 21, 2008, In Brief). The clinical and medical products business includes Alaris infusion pumps, Avea respirators, Pyxis medication dispensing system, surgical gowns and gloves
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.